[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"medical-oncology\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:medical-oncology":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,65],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100466626","a-pilot-and-feasibility-study-of-a-dietary-intervention-with-low-protein-meals-in-cancer-patients-receiving-immunotherapies-100466626",false,"NCT05356182","A Pilot and Feasibility Study of a Dietary Intervention With Low-protein Meals in Cancer Patients Receiving Immunotherapies","Inclusion Criteria:\n\n* Histologically documented solid tumor malignancies which is amenable for immunotherapy treatment with immune checkpoint inhibitors (i.e. PD1, PD-L1, CTLA inhibitors) as single agents or in combination.\n* Metastatic disease as evidenced by soft tissue and\u002For bony metastases on baseline bone scan and\u002For computed tomography (CT) scan of the chest, abdomen, and pelvis\n* Life expectancy of at least 6 months\n* Adults ≥ 18 years of age\n* Adequate hematologic, renal, and liver function as evidenced by the following:\n\n  * White blood cell (WBC) ≥ 2,500 cells\u002FμL\n  * Absolute neutrophil count (ANC) ≥ 1,000 cells\u002FμL\n  * Platelet Count ≥ 100,000 cells\u002FμL\n  * Hemoglobin (HgB) ≥ 9.0 g\u002FdL\n  * Creatinine ≤ 2.0 mg\u002FdL\n  * Total bilirubin ≤ 2 x upper limit of normal (ULN)\n  * Aspartate aminotransaminase (AST, SGOT) ≤ 2.5 x ULN\n  * Alanine aminotransaminase (ALT, SGPT) ≤ 2.5 x ULN\n\nExclusion Criteria:\n\n* • Eastern Cooperative Oncology Group (ECOG) performance status 2 or higher\n\n  * Treatment with any of the following medications or interventions within 28 days of registration:\n\n    * Systemic corticosteroids; however, use of inhaled, intranasal, and topical steroids is acceptable.\n    * High dose calcitriol \\[1,25(OH)2VitD\\] (i.e., \\> 7.0 μg\u002Fweek)\n  * A requirement for systemic immunosuppressive therapy for any reason\n  * Any infection requiring parenteral antibiotic therapy or causing fever (temperature \\> 100.5°F or 38.1°C) within 1 week prior to registration\n  * A known allergy, intolerance, or medical contraindication to receiving the contrast dye required for the protocol-specified CT imaging\n  * Any medical intervention or other condition which, in the opinion of the Principal Investigator, could compromise adherence with study requirements or otherwise compromise the study's objectives","ALL","18 Years",{"count":18,"type":19},30,"ESTIMATED","INTERVENTIONAL",[22],"NA","The main idea of this study is that a low protein diet may alter the environment surrounding the tumor, enhancing the body's immune response leading to greater anticancer effects of treatment. This study intends to use a low-protein diet as a tool to enhance the immune response generated by immune check point inhibitor treatments.",[25,26,27],"Medical Oncology","Integrative Oncology","Medical Nutrition Therapy",[29,30,31],"Oncology","Nutrition","Immunotherapy","RECRUITING","2026-03-30",{"date":35,"type":36},"2026-04-03","ACTUAL",{"date":38,"type":36},"2022-05-04",{"date":40,"type":19},"2028-02",{"name":42,"class":43},"State University of New York at Buffalo","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":20,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},"100466907","a-pilot-feasibility-study-of-intermittent-caloric-restriction-plus-plant-based-diet-in-cancer-patients-receiving-chemotherapy-100466907","NCT05359848","A Pilot, Feasibility Study of Intermittent Caloric Restriction Plus Plant-based Diet in Cancer Patients Receiving Chemotherapy","A Pilot, Feasibility Study of Intermittent Caloric Restriction Plus Plant-based Protein Diet in Cancer Patients Receiving Chemotherapy","Inclusion Criteria:\n\n* • Histologically documented, cancer patients who are eligible to receive cytotoxic chemotherapy.\n\n  * Life expectancy of at least 6 months\n  * Adults ≥ 18 years of age\n  * Adequate hematologic, renal, and liver function as evidenced by the following:\n\n    * White blood cell (WBC) ≥ 2,500 cells\u002FμL\n    * Absolute neutrophil count (ANC) ≥ 1,000 cells\u002FμL\n    * Platelet Count ≥ 100,000 cells\u002FμL\n    * Hemoglobin (HgB) ≥ 9.0 g\u002FdL\n    * Creatinine ≤ 2.0 mg\u002FdL\n    * Total bilirubin ≤ 2 x upper limit of normal (ULN)\n    * Aspartate aminotransaminase (AST, SGOT) ≤ 2.5 x ULN\n    * Alanine aminotransaminase (ALT, SGPT) ≤ 2.5 x ULN\n\nExclusion Criteria:\n\n* • Eastern Cooperative Oncology Group (ECOG) performance status 2 or higher\n\n  * Treatment with any of the following medications or interventions within 28 days of registration:\n\n    * Systemic corticosteroids; however, use of inhaled, intranasal, and topical steroids is acceptable.\n    * High dose calcitriol \\[1,25(OH)2VitD\\] (i.e., \\> 7.0 μg\u002Fweek)\n  * Any infection requiring parenteral antibiotic therapy or causing fever (temperature \\> 100.5°F or 38.1°C) within 1 week prior to registration\n  * A known allergy, intolerance, or medical contraindication to receiving the contrast dye required for the protocol-specified CT\u002FMRI imaging\n  * Any medical intervention or other condition which, in the opinion of the Principal Investigator, could compromise adherence with study requirements or otherwise compromise the study's objectives",{"count":18,"type":19},[22],"Caloric restriction may alter the response to chemotherapy induced stress response and enhance its antitumor effect. This study intends to use an intermitted caloric restriction protocol with alternate days before the chemotherapy administration to enhance the cytotoxic effect generated by standard treatment of cancer.",[25,26,27],"2026-02-18",{"date":58,"type":36},"2026-02-20",{"date":60,"type":36},"2022-04-15",{"date":62,"type":19},"2027-06-01",{"name":42,"class":43},2,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":15,"minAge":73,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":20,"phases":76,"briefSummary":78,"conditions":79,"keywords":83,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":93},"100523580","phase-2-improvement-of-quality-of-life-by-cannabinoids-in-oncologic-patients-100523580","NCT06097533","Improvement of Quality of Life by Cannabinoids in Oncologic Patients","Improvement of Quality of Life by Cannabinoids in Oncologic Patients (BEfindLichkeitsverbesserung Unter CANnabinoid-ExtrakTen Bei Onkologischen Patienten)","BELCANTO","Inclusion Criteria:\n\n* ≥25 years old and legally competent\n* Palliative oncological therapy\n* ECOG status 1, 2 or 3, incapacitated for work\n* ESAS TSDS \\> or equals 16\n* Nutritional Risk Screening \\> or equals 3\n* Pain numerical rating scale \\> or equals 4\n* informed consent\n* for WOCBP:\n\n  * Negative pregnancy test\n  * Reliable contraception (Pearl Index \\\u003C 1%)\n\nExclusion Criteria:\n\n* nausea \\> or equals grade 3 (CTCAE) or vomiting \\> or equals grade 2 (CTCAE) in the preceding week\n* Inability to understand and complete the questionnaires\n* Cannabis use in the last 6 weeks\n* Alcohol addiction\n* Pregnancy\u002Flactation\n* Contraindications or intolerance to the study medication (esp. psychosis)\n* Simultaneous participation in other clinical studies (sumulataneous participation in non-interventional studies (i.e. biomarker-studies, registries) is allowed, if the study-aim does not interfere with measures of the second study)\n* Any other condition as judged by the investigator, e.g. non-compliance","25 Years",{"count":75,"type":19},170,[77],"PHASE2","The goal is to explore whether the application of cannabis extract Avextra 10\u002F10 solution is suitable to contribute to an improvement in the symptom burden and well-being of oncological palliative care patients. The primary objective of the study is to demonstrate the improvement in global symptom burden in the intervention arm compared to the placebo control group over a period of 12±2 days, as measured by a percentage change in the value of the Edmonton Symptom Assessment System total symptom distress score (ESAS TSDS) at baseline and after 12±2 days.",[25,80,81,82],"Palliative Care","Quality of Life","Cannabinoids",[71],"2024-10-23",{"date":86,"type":36},"2024-10-26",{"date":88,"type":36},"2024-04-08",{"date":90,"type":19},"2026-11-30",{"name":92,"class":43},"University Hospital Schleswig-Holstein",4]